Immunohistochemistrybased assessment of androgen receptor status and the ARnull phenotype in metastatic castrate resistant prostate cancer

Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer

17:35 EST 24 Feb 2020 | Nature Publishing

More From BioPortfolio on "Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer"